AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
China has entered the United Nations’ annual list of the world’s ten most innovative nations for the first time, displacing Germany, Europe’s la...
The European Commission will delay presenting its next Russia sanctions package, European Union officials said on Tuesday, as the bloc searches for a ...
Flash floods unleashed by a sudden cloudburst in India’s Himalayan state of Uttarakhand on Tuesday (September 16) swept away villages and marketplac...
Spain’s Foreign Ministry announced it will summon Israel’s charge d’affaires on Tuesday to protest remarks made by Israeli Foreign Minister Gide...
Russian Tu-160 bombers practised launching cruise missiles over the Barents Sea on Tuesday during joint military drills with Belarus, as part of the Z...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
AnewZ has learned that India has once again blocked Azerbaijan’s application for full membership in the Shanghai Cooperation Organisation, while Pakistan’s recent decision to consider diplomatic relations with Armenia has been coordinated with Baku as part of Azerbaijan’s peace agenda.
A day of mourning has been declared in Portugal to pay respect to victims who lost their lives in the Lisbon Funicular crash which happened on Wednesday evening.
A Polish Air Force pilot was killed on Thursday when an F-16 fighter jet crashed during a training flight ahead of the 2025 Radom International Air Show.
At least eight people have died and more than 90 others were injured following a catastrophic gas tanker explosion on a major highway in Mexico City’s Iztapalapa district on Wednesday, authorities confirmed.
The World Health Organization has started vaccinating frontline health workers and contacts of Ebola patients in the Democratic Republic of Congo’s Kasai province, where the virus outbreak has already claimed 16 lives.
Japan has reached a record 99,763 centenarians as of September 1, with women accounting for roughly 88 percent, marking the 55th consecutive year the country has hit this milestone.
The World Health Organization has added GLP-1 drugs to treat diabetes to its essential medicines list, alongside treatments for cystic fibrosis and cancer, and said it hopes this will improve global access to the costly drugs.
Zambia has formalised a strategic partnership with the International Vaccine Institute (IVI) to bolster domestic vaccine manufacturing capacity, the Zambia National Public Health Institute (ZNPHI) announced on Friday.
Four-time Tour de France winner Chris Froome was airlifted to hospital in Toulon after suffering a training crash which left him with broken ribs, a collapsed lung and a back fracture, his team Israel-Premier Tech said on Thursday (August 28).
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment